Endocrine AEs, which are particularly significant because they may require long-term hormone therapy, were also reported, with hypophysitis (most likely attributed to the impact of ipilimumab [23]) and thyroid dysfunction (frequent among patients receiving anti-PD-1 therapy [11]) being the most common. Here, PDCD1 is linked to hypophysitis.